Progress of minimal residual disease detection in multiple myeloma
10.3760/cma.j.cn115356-20200619-00619
- VernacularTitle:多发性骨髓瘤微小残留病检测研究进展
- Author:
Wenqiang YAN
;
Gang AN
- From:
Journal of Leukemia & Lymphoma
2021;30(1):58-61
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, with the application of a variety of new drugs, the prognosis of patients with multiple myeloma (MM) has been significantly improved, and the survival time has been significantly prolonged, but almost patients will relapse eventually. The persistent existence of minimal residual disease (MRD) is considered to be the root cause of disease recurrence. Therefore, the detection of MRD in MM patients is of great clinical significance, which would contribute to evaluate the efficacy of MM, accelerate clinical trials, dynamic risk stratification, and further guide the treatment strategy. However, until now, there are no standard method and evaluation criteria of MRD detection. This review focuses on the advantages and disadvantages of different methods,clinical applications and future development direction of MRD detection in MM.
